28 May 2015
(Oxford, UK, 28 May 2015) Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer, viral infections and autoimmune disease, announces that its Chief Scientific Officer and co-founder, Dr. Bent Jakobsen, has been recognised for his contribution to medical science with an election to the Fellowship of the Academy of Medical Sciences.
Through decades of research, Dr Jakobsen has been instrumental in the development of Immunocore’s unique immuno-oncology platform technology, ImmTACs, and has contributed significantly to scientific advances in T cell receptor technology more broadly. This technology has the potential to create breakthrough treatments for diseases with high unmet medical need including cancer, viral infections and autoimmune diseases.
Dr. Eliot Forster, Chief Executive Officer of Immunocore, commented: “Bent Jakobsen’s contribution to the field of immuno-oncology through his work with both Immunocore and its sister company Adaptimmune is hard to over-estimate. He has been instrumental in establishing proof of concept for the T cell receptor technology which is at the heart of both companies’ technology platforms. He has played a central role in helping form Immunocore and in bringing our most advanced drug candidate, IMCgp100, to the clinic. We are delighted that he has been recognized by the Academy of Medical Sciences for this work.”
Dr. Bent Jakobsen said: “I am honoured to have been elected to a Fellowship of such a prestigious institution, and I hope that this recognition will help to further awareness of the advances we are making at Immunocore, and in T cell receptor technology across the board and the promise it holds for cancer patients.”
Please click on the link below to download the full Press Release: